Results 221 to 230 of about 12,268,158 (295)

Blood SOD1 Activity in ALS Patients Receiving Tofersen Treatment

open access: yesAnnals of Neurology, EarlyView.
Objective The antisense oligonucleotide tofersen is the first disease‐modifying drug for SOD1‐related amyotrophic lateral sclerosis (ALS) and was approved because of its ability to reduce SOD1 protein and neurofilament levels. The effect of tofersen on SOD1 activity is unclear but of clinical relevance because homozygous SOD1 mutations, linked to ...
Katharina Goehring   +18 more
wiley   +1 more source

Neutrophil Extracellular Traps Block Fibrinolysis in Ischemic Stroke

open access: yesAnnals of Neurology, EarlyView.
Objectives Intravenous thrombolysis (IVT) failure in acute ischemic stroke (AIS) is frequent, but its causes remain elusive. We investigated whether biologically relevant intrathrombus concentrations of tissue plasminogen activator (tPA) were achieved in failed IVT and whether neutrophil extracellular traps (NETs) contributed to this therapeutic ...
Mialitiana Solo Nomenjanahary   +21 more
wiley   +1 more source

Adjunctive Pharmacotherapy for Major Depressive Disorder with Anxiety Symptoms: from Monoamines to Recent Clinical Evidence. [PDF]

open access: yesCNS Drugs
McIntyre RS   +7 more
europepmc   +1 more source

Modulating Local Coordination in Single‐Atom Catalysts: From Fundamental Concepts to Emerging Breakthroughs in Electrocatalysis

open access: yesAngewandte Chemie, EarlyView.
This review summarizes atomic‐level design strategies for single‐atom catalysts, emphasizing modulation of the local coordination environment, active‐site geometry, and metal‐support interactions to optimize catalytic activity and stability in electrocatalytic energy conversion applications.
Ashwani Kumar, Harun Tüysüz
wiley   +1 more source

Serotonin Transporter Blockade Reduces the Psychedelic-Like Effects of 4-Methoxy-<i>N</i>-methyl-<i>N</i>-isopropyltryptamine and Related Analogs. [PDF]

open access: yesACS Chem Neurosci
Glatfelter GC   +11 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy